[go: up one dir, main page]

MXPA05010070A - Combinacion farmaceutica. - Google Patents

Combinacion farmaceutica.

Info

Publication number
MXPA05010070A
MXPA05010070A MXPA05010070A MXPA05010070A MXPA05010070A MX PA05010070 A MXPA05010070 A MX PA05010070A MX PA05010070 A MXPA05010070 A MX PA05010070A MX PA05010070 A MXPA05010070 A MX PA05010070A MX PA05010070 A MXPA05010070 A MX PA05010070A
Authority
MX
Mexico
Prior art keywords
eletriptan
sodium bicarbonate
pharmaceutical combination
combination
prevention
Prior art date
Application number
MXPA05010070A
Other languages
English (en)
Inventor
John Humphrey Michael
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA05010070A publication Critical patent/MXPA05010070A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El presente invento proporciona una combinacion de (a) eletriptan, o una de sus sales farmaceuticamente aceptables, y (b) bicarbonato de sodio; la combinacion proporciona una absorcion rapida de eltriptan cuando se toma por via oral; la combinacion es util para el tratamiento o la prevencion de una enfermedad para la que es indicado un agente agonista de 5-HT1, particularmente en el tratamiento de una migrana o para la prevencion de una recurrencia de migrana.
MXPA05010070A 2003-04-11 2004-03-31 Combinacion farmaceutica. MXPA05010070A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination
PCT/IB2004/001115 WO2004089365A1 (en) 2003-04-11 2004-03-31 Pharmaceutical combination comprising eletriptan and sodium bicarbonate

Publications (1)

Publication Number Publication Date
MXPA05010070A true MXPA05010070A (es) 2005-11-23

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010070A MXPA05010070A (es) 2003-04-11 2004-03-31 Combinacion farmaceutica.

Country Status (12)

Country Link
EP (1) EP1615635A1 (es)
JP (1) JP2006522790A (es)
AR (1) AR044009A1 (es)
BR (1) BRPI0409127A (es)
CA (1) CA2521902A1 (es)
MX (1) MXPA05010070A (es)
NL (1) NL1025908C2 (es)
PA (1) PA8599901A1 (es)
PE (1) PE20050086A1 (es)
TW (1) TW200423929A (es)
UY (1) UY28260A1 (es)
WO (1) WO2004089365A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
JP6878021B2 (ja) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 トリプタンとアスコルビン酸を含有する医薬組成物
MY199007A (en) * 2018-07-03 2023-10-09 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
EP3920909A4 (en) * 2019-02-06 2022-11-30 Axsome Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (it) * 1986-08-01 1988-11-25 Zambon Spa Composizione farmaceutica ad attivita' analgesica
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
CO5261541A1 (es) * 1999-05-14 2003-03-31 Pfizer Prod Inc Terapia de combinacion para el tratamiento de la migrana
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
JP2006523620A (ja) * 2003-02-19 2006-10-19 バイオヴェイル ラボラトリーズ インコーポレイテッド 急速吸収選択的５−ｈｔ作用剤製剤

Also Published As

Publication number Publication date
NL1025908A1 (nl) 2004-10-13
PA8599901A1 (es) 2005-02-04
CA2521902A1 (en) 2004-10-21
JP2006522790A (ja) 2006-10-05
UY28260A1 (es) 2004-11-30
AR044009A1 (es) 2005-08-24
BRPI0409127A (pt) 2006-03-28
WO2004089365A1 (en) 2004-10-21
PE20050086A1 (es) 2005-03-01
EP1615635A1 (en) 2006-01-18
TW200423929A (en) 2004-11-16
NL1025908C2 (nl) 2005-11-22

Similar Documents

Publication Publication Date Title
BE2019C008I2 (es)
UA84141C2 (ru) Применение ингибитора пктжк для лечения или профилактики запора
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
MXPA03010285A (es) Derivados de furano y tiofeno que activan receptores activados por el proliferador de peroxisoma humana.
MXPA04005877A (es) Composiciones farmaceuticas de derivados de taxano oralmente activos con biodisponibilidad mejorada.
WO2005007137A3 (de) Ambroxolhaltige tabletten
IN2005KO00312A (es)
AU2003221042A1 (en) Preventive or therapeutic agent for kidney disease
MY137620A (en) Therapeutic treatment
MXPA05010070A (es) Combinacion farmaceutica.
EA200201149A1 (ru) Фармацевтические композиции и способы для предотвращения рецидива мигрени
AR038305A1 (es) Composicion farmaceutica dispersable oralmente de perindopril
MY135441A (en) Therapeutic treatment
MY136288A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
MA27262A1 (fr) Microcapsules pour la liberation retardee et controlee du perindopril
SE0102855D0 (sv) Method of treatment
DOP2004000871A (es) Combinacion farmaceutica
EE200400069A (et) Tsitalopraami kasutamine ravimkoostiste valmistamiseks kõrgenenud vererõhu raviks
MY136989A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
WO2004002486A3 (en) Ciprofloxacin hci
CL2004000751A1 (es) Combinacion farmaceutica que contiene (a) eletripan, o una de sus sales, y (b) bicarbonato de sodio; composicion y producto farmaceutico que contiene a dicha combinacion; y su uso en la preparacion de un medicamento util para el tratamiento y la prev
AR038194A1 (es) Composicion farmaceutica dispersable oralmente de piribedil
AR038208A1 (es) Composicion farmaceutica dispersable oralmente de mitiglinida
MXPA04005310A (es) Inhibidores de fosfolipasa a2 citosolica.

Legal Events

Date Code Title Description
FG Grant or registration